TheraRadar
← Back
Data updated: Jun 28, 2026

ONYX PHARMS AMGEN

Specialty
OncologyImmunologyMetabolic Execution: Good

ONYX PHARMS AMGEN is a specialty pharmaceutical company focused on Oncology, Immunology, Metabolic. Key products include KYPROLIS.

2012
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

ONYX PHARMS AMGEN at a Glance

  • Leading 15 drug targets across portfolio
  • Fast trial execution (27 months median completion)

ONYX PHARMS AMGEN's Key Drugs

ONYX PHARMS AMGEN's core commercial portfolio centers on KYPROLIS, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.

KYPROLIS
Oncology

Multiple Myeloma

20S proteasome Approved 2012

ONYX PHARMS AMGEN's Recent FDA Approvals

New NDA/BLA approvals for ONYX PHARMS AMGEN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ONYX PHARMS AMGEN's Therapeutic Areas

ONYX PHARMS AMGEN's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 42%
1 drugs Phase 3: 49 Phase 2: 30 Phase 1: 111
Immunology 27%
0 drugs Phase 3: 38 Phase 2: 24 Phase 1: 34
Metabolic 18%
0 drugs Phase 3: 26 Phase 2: 12 Phase 1: 29
Cardiovascular 8%
0 drugs Phase 3: 14 Phase 2: 6 Phase 1: 4
Neurology 5%
0 drugs Phase 3: 6 Phase 2: 5 Phase 1: 13

ONYX PHARMS AMGEN's Top Competitors

ONYX PHARMS AMGEN's closest competitors by therapeutic-area and drug-target overlap include Sanofi, Eli Lilly, and Roche. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Sanofi big-pharma
Metabolic, Oncology, Immunology, Cardiovascular
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Roche big-pharma
Oncology, Immunology, Neurology, Metabolic
AstraZeneca big-pharma
Oncology, Metabolic, Cardiovascular, Immunology
Pfizer big-pharma
Oncology, Immunology, Neurology

ONYX PHARMS AMGEN Pipeline Snapshot

ONYX PHARMS AMGEN has 401 active clinical programs from ClinicalTrials.gov — 133 Phase 3, 77 Phase 2 and 191 Phase 1.

133
Phase 3
77
Phase 2
191
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • KYPROLIS leads revenue
  • • Drug-level revenue analysis
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 148/214 completed
  • • Speed: 27 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges